Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy

Abstract

Combining radiotherapy with immune checkpoint blockade may offer considerable therapeutic impact if the immunosuppressive nature of the tumor microenvironment (TME) can be relieved. In this study, we used mathematical models, which can illustrate the potential synergism between immune checkpoint inhibitors and radiotherapy. A discrete-time pharmacodynamic model of the combination of radiotherapy with inhibitors of the PD1-PDL1 axis and/or the CTLA4 pathway is described. This mathematical framework describes how a growing tumor first elicits and then inhibits an antitumor immune response. This antitumor immune response is described by a primary and a secondary (or memory) response. The primary immune response appears first and is inhibited by the PD1-PDL1 axis, whereas the secondary immune response happens next and is inhibited by the CTLA4 pathway. The effects of irradiation are described by a modified version of the linearquadratic model. This modeling offers an explanation for the reported biphasic relationship between the size of a tumor and its immunogenicity, as measured by the abscopal effect (an offtarget immune response). Furthermore, it explains why discontinuing immunotherapy may result in either tumor recurrence or a durably sustained response. Finally, it describes how synchronizing immunotherapy and radiotherapy can produce synergies. The ability of the model to forecast pharmacodynamic endpoints was validated retrospectively by checking that it could describe data from experimental studies, which investigated the combination of radiotherapy with immune checkpoint inhibitors. In summary, a model such as this could be further used as a simulation tool to facilitate decision making about optimal scheduling of immunotherapy with radiotherapy and perhaps other types of anticancer therapies. Cancer Res; 76(17); 4931-40. Ó2016 AACR.

Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis

“…In addition to useful but complex multi-scale approaches, developing simplified PK/PD models with tumor biology kept at its minimal expression to generate configurable parameters is another appealing strategy [14]. Such simplified phenomenological modeling has already proved to be capable of mimicking complicated phenomena [35] and its ability to be implemented at bedside [36–38]. Here, this proof-of-concept study strongly suggests that simplified modeling could help to address the issue of finding the optimal dosing and scheduling with bevacizumab.…”

Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model

“…A discrete-time mathematical model of the combination of radiotherapy with checkpoint inhibitors was developed in [28]. Mathematical models of immunotherapy with a cancer vaccine by a system of ordinary differential equations were developed earlier in [29, 30]; these models do not consider checkpoint inhibitors.…”

Addressing current challenges in cancer immunotherapy with mathematical and computational modelling

“…Models for various combinations of traditional and immunotherapies have been developed [60][61][62][63], which generally build on earlier tumour-immune, monotherapy or even combination therapy models. For example, Chareyron & Alamir [64] extended earlier models developed by de Pillis et al [28,65] to include chemo-and immunotherapy and used control theory to determine optimal therapy protocols, again addressing multiple major challenges discussed herein.…”